UNITED ANTICIPATES FDA PRODUCT APPROVAL.

United Therapeutics (Nasdaq: UTHR), with facilities in Research Triangle Park, announced recently that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended approval of Remodulin Injection for the treatment of pulmonary arterial hypertension by a vote of 6 to 3.

The advisory committee's recommendation will be considered by the FDA during its …